Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06545500 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 7
- Study locations
NCT06545500 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that has completed, run by Verona Pharma. The registered enrollment target is 46 participants, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT06545500, a Phase 2 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Verona Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice daily via standard jet nebulizer over three 1-week active treatment periods and one 1-week placebo period in subjects with chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Glycopyrrolate (85 μg)
- DRUG Glycopyrrolate (42.5 μg)
- DRUG Glycopyrrolate (14 μg)
Study Locations (7)
South Carolina
- Velocity Clinical Research - Greenville - Greenville
- Velocity Clinical Research - Spartanburg - Spartanburg
- Velocity Clinical Research - Union - Union
Florida
- Clinical Research of West Florida Inc - Clearwater - Clearwater
- Clinical Research of West Florida Inc - Tampa - Tampa
Missouri
- Midwest Chest Consultants PC - Saint Charles
North Carolina
- American Health Research Inc - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06545500
The ClinicalTrials.gov registry entry for NCT06545500 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (97% lower). The listed sponsor is Verona Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06545500 reports 7 study locations spanning 4 distinct geographic areas - top geographies include South Carolina, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT06545500 about?
NCT06545500 is a clinical study titled "A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD". This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice daily via standard jet nebulizer over three 1-week active treatment period...
What is the current status of trial NCT06545500?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-08-16. Estimated completion is 2025-01-08.
What conditions does trial NCT06545500 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT06545500?
The interventions under investigation include: Placebo (DRUG), Glycopyrrolate (85 μg) (DRUG), Glycopyrrolate (42.5 μg) (DRUG), Glycopyrrolate (14 μg) (DRUG).
Who is sponsoring clinical trial NCT06545500?
This trial is sponsored by Verona Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06545500 being conducted?
This trial has 7 study locations across Florida, Missouri, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.